eyeDNA Presents 2-Year HORA-PDE6b Gene Therapy Results at ARVO 2024

The Association for Research in Vision and Ophthalmology (ARVO) is set to host its annual meeting, offering a comprehensive platform for attendees to explore and select sessions of interest. This digital planner allows for personalized itineraries, enabling users to search through session titles and descriptions, apply filters based on session types and sections, and save their choices. To utilize the full functionality, including saving sessions and abstracts, users must log in with their ARVO credentials.
During the ARVO 2024 meeting in Seattle, WA, USA, eyeDNA Therapeutics, a subsidiary of Coave Therapeutics, will present significant findings from a Phase I/II clinical trial. The study focuses on HORA-PDE6b, an experimental gene therapy for retinitis pigmentosa (RP), a genetic eye disorder caused by mutations in the PDE6B gene. The results from 12-month and 24-month follow-ups will be shared in an oral presentation, highlighting the therapy's safety and efficacy.
Dr. Jean-Baptiste Ducloyer, an expert from Nantes University's Department of Ophthalmology in France, will deliver the presentation. The session is scheduled for Monday, May 6, 2024, from 3:30 PM to 3:45 PM Pacific Daylight Time, in Room 612 at the Seattle Convention Center's Arch Building. The abstract for the presentation is accessible through the ARVO meeting's online planner.
eyeDNA Therapeutics is dedicated to crafting transformative treatments for inherited retinal diseases. Their flagship program, HORA-PDE6b, employs an AAV5-based gene replacement approach and is currently undergoing a Phase I/II trial. The company collaborates with Théa Open Innovation for the development and commercialization of the therapy, with eyeDNA overseeing global development and holding commercial rights in several countries, while Théa Open Innovation is responsible for European markets.
Coave Therapeutics, the parent company, is pioneering the expansion of genetic medicine to address both rare and common conditions, with a focus on neurodegenerative and eye diseases. Their innovative ALIGATER™ platform enhances AAV capsids and Lipid Nanoparticles to improve the efficacy, safety, and manufacturability of gene therapies. Coave's advanced vectors have shown promising results in the central nervous system and the eye, offering hope for patients with various neurodegenerative and ocular diseases. The company has established eyeDNA Therapeutics to concentrate on the development and marketing authorization of HORA-PDE6b.
Coave Therapeutics is headquartered in Paris and is supported by prominent life sciences investors.